Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Tremfya (guselkumab) for the treatment of patients with Crohn’s disease
- Tremfya (guselkumab) for the treatment of patients with ulcerative colitis (UC)
- Oxlumo (lumasiran) for the treatment of patients with primary hyperoxaluria type 1
- Tecentriq (atezolizumab) + atezolizumab for the treatment of patients with lung cancer and pleural mesothelioma
- Keytruda (pembrolizumab) for the treatment of patients with hepatocellular carcinoma or cholangiocarcinoma
- Welireg (belzutifan) for the treatment of patients with von Hippel-Lindau disease
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
